Search Within

Sergio Andres Giralt

  1. "Malin Hultcrantz"
Formats
  1. Meeting Abstract (101)
  2. Journal Article (21)
  3. Research Letter (5)
  4. Correspondence (2)
Groups
  1. Bone Marrow Transplant (129)
  2. Center for Hematologic Malignancies (129)
  3. Department of Medicine (129)
  4. Hematologic Malignancies Research (129)
  5. Hematologic Malignancies, Division of (129)
  6. Myeloma (129)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Malin Hultcrantz (129)
  3. Sham Mailankody (127)
  4. Neha Korde (126)
  5. Hani Hassoun (125)
  6. Heather Landau (122)

More People

Years
  1. 2025 (6)
  2. 2024 (34)
  3. 2023 (32)
  4. 2022 (23)
  5. 2021 (12)
  6. 2020 (8)

More Years

Publications
  1. Blood (56)
  2. Clinical Lymphoma, Myeloma and Leukemia (36)
  3. Journal of Clinical Oncology (9)
  4. Blood Cancer Journal (6)
  5. Blood Advances (5)
  6. American Journal of Hematology (2)

More Publications

Publishers
  1. American Society of Hematology (61)
  2. Elsevier Inc. (41)
  3. American Society of Clinical Oncology (9)
  4. Nature Publishing Group (7)
  5. American Association for Cancer Research (2)
  6. John Wiley & Sons, Inc. (2)

More Publishers

Results (129)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Journal Article

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; more...
    Blood Neoplasia (2025)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
    Correspondence

    Sebastian, T.; Rajeeve, S.; Farzana, T.; Firestone, R.; Jurgens, E.; Miller, K.; Costa, B.; Lesokhin, A.; Tan, C.; Shah, G.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save